S&P 500
5.537,02 +28,01 (+0,51%) Nasdaq
18.188,30 +159,54 (+0,88%) NIKKEI 225
40.913,65 +332,89 (+0,82%) Dólar/Euro
1,0814 +0,0027 (+0,25%) Petróleo Brent
87,52 +0,18 (+0,21%) Bitcoin EUR
53.731,66 -1.951,66 (-3,50%)
LivaNova PLC (LIVN)
Después del cierre:
LivaNova PLC
20 Eastbourne Terrace
London W2 6LG
United Kingdom
44 20 3325 0660
https://www.livanova.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 2900
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alex Shvartsburg | Chief Financial Officer | 1,2M | N/A | 1970 |
| Mr. Michael D. Hutchinson | Senior VP, Chief Legal Officer & Company Secretary | 1,09M | N/A | 1971 |
| Ms. Trui Hebbelinck | Chief Human Resources Officer | 895,05k | N/A | 1973 |
| Mr. Vladimir A. Makatsaria | CEO & Director | N/A | N/A | 1973 |
| Mr. Badri Amurthur | Chief Technology Officer | N/A | N/A | N/A |
| Lindsey Little | Senior Director of Investor Relations | N/A | N/A | N/A |
| Deanna Wilke | Vice President of Corporate Communications | N/A | N/A | N/A |
| Mr. Matthew Joseph Dodds III | Senior Vice President of Corporate Development & IT | N/A | N/A | N/A |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | N/A | N/A | 1956 |
| Ms. Stephanie Bolton | President of Global Epilepsy | N/A | N/A | 1982 |
Descripción
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de LivaNova PLC, a día 1 de julio de 2024, es 2. Las puntuaciones base son Auditoría: 3; Tablero: 1; Derechos de los accionistas: 3; Compensación: 3.
